Comparison of Glyceryl Trinitrate Versus Misoprostol for Cervical Ripening in Diagnostic Curettage

Comparison of Glyceryl Trinitrate Versus Misoprostol for Cervical Ripening in Diagnostic Curettage, A single blind clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201105049276N1

Enrollment

168

Registered

2020-11-10

Start date

2020-10-14

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Ripening.

Interventions

Intervention 1: Intervention group: TNG recipients will receive three doses of vaginal TNG (manufactured by Zahravi Pharmaceutical Company) at 1200 micrograms (every 3 hours). Intervention 2: Interven

Eligibility

Sex/Gender

Female

Age

35 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 35 years No allergy history to Glyceryl Trinitrate and Misoprostol Hb > 10 g/dl Closure of the cervix Consent to participate in the study

Exclusion criteria

Exclusion criteria: Abnormalities in patient’s test results including coagulation and CBC disorders Special medical conditions such as severe anemia, coagulation disorders, glaucoma, and bronchial asthma PID presence ( endometritis , salpingitis , ..) and vaginal infection

Design outcomes

Primary

Measure	Time frame
Ease of cervical ripening. Timepoint: 6 Hours after administration. Method of measurement: Hegar Dilator size ( mm).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Azam Amini

Gorgan University of Medical Sciences

pfarjad13@gmail.com+98 17 3220 2565

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026